All News
RFK Jr.'s Vaccine Panel to Study Childhood Immunization Schedule
(MedPage Today) -- Leadership of the CDC's new vaccine advisory committee announced the creation of two new workgroups, including one looking at the cumulative effects of the childhood vaccination sc
Read MoreSTAT+: Trump’s pick to run the CDC walks a fine line on RFK Jr. at Senate hearing
Monarez was careful with her words at a Senate hearing on her nomination to run the CDC.
Read MoreNew and Improved Navitor Makes for a Serious TAVR Contender
(MedPage Today) -- NEW YORK CITY -- The newer Navitor looked increasingly viable as a transcatheter aortic valve replacement (TAVR) system, based on its largest report of commercial use to date.
Read MoreRisk Prediction Model for Early Hodgkin's Lymphoma Outperforms Widely Used Standard
(MedPage Today) -- A prognostication tool for early classic Hodgkin's lymphoma (cHL) outperformed a widely used classification system in predicting 2-year progression-free survival (PFS), according t
Read MoreN.I.H. Memo Pauses Cancellations of Medical Research Grants
The directive, in a memo issued Tuesday, came after two court rulings that questioned the Trump administration’s swift cuts to funding.
Read MoreSTAT+: NIH halts grant terminations ‘effective immediately,’ email says
The National Institutes of Health is halting further terminations of research grants, an internal email shows
Read MorePsilocybin Win in Depression; Top Industries for Mental Distress; Heatwaves and Mood
(MedPage Today) -- A single dose of synthetic psilocybin significantly reduced symptoms of treatment-resistant depression in a 6-week phase III trial, said developer Compass Pathways.
Read MoreMember of RFK Jr’s new vaccine panel withdraws over conflict of interest
Dr Michael Ross was involved in multiple private healthcare firms and withdrew after a review of financial holdingsA member of the health secretary Robert F Kennedy Jr’s newly overhauled federal vac
Read MoreSTAT+: Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game
Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.
Read More